1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €8.63 (-65.31%). The median is €8.63 (-65.31%).
| Buy |
11 |
| Hold |
8 |
| Sell |
0 |
News Go to news feed
Mersana Therapeutics releases quarterly results for Sept. 30, 2025 – analysts expect smaller loss per share
Mersana Therapeutics will publish results for the quarter ended Sept. 30, 2025 on Nov. 14, 2025. Eight analysts on average expect earnings per share of -$1.544, an improvement of 31.38% from the year-ago quarter (-$2.250). Nine analysts estimate quarterly revenue at an average of $14.2 million (up 12.7% from $12.6 million). For the current fiscal year analysts expect on average a loss of -$6.784 per share and revenue of around $25.3 million (prior year: $40.5 million). » More on finanzen.net
Financials
| (EUR) | Sep 2025 | |
|---|---|---|
| Revenue | 9.38M | - |
| Gross profit | 9.38M | - |
| Net profit | -6.43M | - |
| EBITDA | -6.02M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €125.46M |
Number of shares | 5M |
52-week high/low | €26.23 - €4.50 |
| Dividends | No |
Beta | 0.43 |
P/E ratio | -2.59 |
PEG ratio | -0.35 |
P/B ratio | -2.44 |
P/S ratio | 8.64 |
Company profile
| Name | Mersana Therapeutics Inc |
| CEO | Martin H. Huber |
| Employees | 102 |
Discover assets
Shareholders of Mersana Therapeutics Inc also invest in the following assets
